Vancouver, British Columbia--(Newsfile Corp. - December 6, 2018) - Alliance Growers Corp. (CSE: ACG) (FSE: 1LA) (WKN:
A2DFYX) (OTCQB: ALGWF) ("Alliance" or "the Company") is pleased to announce how the Company's cutting edge facility will contribute
to the maximization of the supply of quality cannabis production with the use of tissue culture starter plantlets to be produced at
the Company's Cannabis Biotech Complex, in B.C., Canada. The Cannabis Biotech Complex, being developed with its partner, WFS
Pharmagreen Inc. ("Pharmagreen") is under construction and is anticipated to be completed in Q1 2020. The company also wants to
take the opportunity to inform shareholders that it is on track to file its financial statements, management discussion and
analysis, and certifications of annual filings for the year ended August 31st, 2018 (collectively, the "2018 Financials"), on or
before December 20, 2018, ahead of the December 31 deadline.
Commenting on Alliance Growers' business strategy, Dennis Petke, President and CEO, stated, "The cannabis market space is
growing at a rapid pace and supply issues are becoming a serious problem for both medical and recreational cannabis. Alliance
Growers' strategy is to be positioned where the market is going, and not where it is today, and this is being accomplished
primarily via the development of the Cannabis Biotech Complex. Supply issues, due to contamination, further confirm the need to
supply growers with the highest quality tissue cultured plantlets, along with other revolutionary and beneficial services from the
facility to maximize each and every crop of all growers who utilize tissue cultured plantlets for their starts. We are pleased with
the progress and new financing initiatives being developed recently by both Pharmagreen and Alliance, the details of which will be
disclosed in due course. We look forward to 2019 being the year that the joint vision of the two respective companies is realized
and significant value is created for all stakeholders."
Recently cannabis industry news indicates that certain significant producers of cannabis have experienced production problems,
such as mildew and mold, resulting in a negative financial impact to these producers. The Tissue Culture Facility, the main
component of the Cannabis Biotech Complex, has been designed to minimize, if not eliminate problems such as these, through its
world class engineered clean-room level production facility. The facility will produce tissue cultured plantlets for sale to
medical and recreational licensed producers which are healthy, disease fee and pesticide free. Doing so will enable growers to
produce high quality crops which will meet, or exceed, Health Canada production standards. This allows producers to maintain their
crop cycles and minimize contamination risks that would otherwise cause them to be unable to meet production obligations, as was
recently experienced by large cannabis producers. As a result, the use of tissue cultured plantlets will contribute significantly
to maintaining a healthy and consistent supply to the public, which is currently a major issue.
Growers can also maximize their production space by eliminating the need for mothers and clones' rooms thereby increasing their
flowering space as much as 20% in some cases. Recovering this space for growing would contribute positively to the revenue of
producers.
The Cannabis Biotech Complex will also provide cultivation consulting services. This service will focus on the development of
optimal nutrients and cultivation schedules for our client's proprietary strains, as well as Pharmagreen's strains. Having the
optimal cultivation protocols for each strain under cultivation greatly reduces the risk of potential nutrient lockup, which can
stunt the plants growth and cause a reduction in plant size and yield. For those seeking additional protection from potential loss
of proprietary strains due to plant theft or plant death or for long term off-site genetics preservation in a lab environment, the
Cannabis Biotech Complex will offer a proprietary service of live tissue cultures storage with its cold storage technology.
Alliance Growers is also excited about its partnership with Pharmagreen to produce quality hemp from the "CBD Dana" strain. The
"CBD Dana" strain will be produced with all female plantlets, for commercial production of hemp biomass which can be used to
produce 99% CBD crystallite. In either form, thanks to the high CBD content of as much as 14% CBD and less than 0.3% THC, the
production of CBD Dana has significant revenue potential for the Company as it can be distributed globally without onerous
regulatory requirements currently in place for marijuana plants. "CBD Dana" hemp plants can yield close to 200 kg of CBD Isolate in
one acre, as opposed to planting from hemp seed which yields approximately 7 KG of CBD Isolate per acre. "CBD Dana" strain is a
hemp plant that by design, allows for international shipping of plantlets without restrictions to the world's largest CBD market,
the United States. This proprietary strain, meeting FDA requirements in the U.S., for CBD consumer products to be derived from hemp
plants makes "CBD Dana" strain, with female plants only, the optimal CBD farming model.
The current retail cannabis industry status in Canada is at its infancy stages with the recent legalization on October 17, 2018
and as the home grower market expands in the next 24 months, the Cannabis Biotech Complex will be a future supply source of
guaranteed no pests, no diseases, certified genetics, tissue cultured starter plantlets for the Canadian home-grown market. It is
committed to ensuring that the public is provided with a consist ecologically sound product and that producers, in doing so, can
meet their production obligations and maximize revenue in this burgeoning market.
About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.
WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded company.
WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue
culture process with opportunity to become one of the largest players globally. Pharmagreen's mission is to advance the technology
of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of
cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low
temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver
laboratory based services to the North American Cannabis and agriculture sectors. For further information on the company progress
on the construction of a 62,000 square foot "Cannabis Biotech Complex" please visit www.pharmagreen.ca
About Alliance Growers Corp.
Alliance Growers is a Diversified Global Medical Cannabis Company driven by the Company's 'Four Pillars' Organization Plan -
Cannabis Biotech Complex, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Technology.
Alliance Growers is working with Pharmagreen Biotech Inc. advancing a new business partnership, to jointly develop and operate a
62,000-square foot facility, to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and
Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis
Biotech Complex's main facility is the Cannabis Biotech Centre which will grow Cannabis plantlets using proprietary tissue culture
propagation, specifically utilizing the "Chibafreen Invitro Plant Production System", which allows for more tissue cultured
plantlets to be produced in less space and less time.
For further information, please visit the Company's website at www.alliancegrowers.com or the Company's profile at www.sedar.com.
If you would like to be added to Alliance Growers' news distribution list, please send your email address to newsletter@alliancegrowers.com.
For more information contact:
Dennis Petke
CEO, President and Director
Tel: 778-331-4266
DennisPetke@alliancegrowers.com
Rob Grace
Communications Consultant
Tel: 778-998-5431
RobDGrace@gmail.com
FOLLOW US:
Facebook
Twitter
LinkedIn
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS
RELEASE
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future performance. All statements other than statements of historical
fact may be forward-looking statements or information. More particularly and without limitation, the news release contains
forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information
are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the
Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions
on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the
forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations
and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and
information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and
information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could
differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the
Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks
associated with the medical marijuana industry in general, such as operational risks in development and production delays or
changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the
uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing
and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market;
ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals
and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place
undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned
that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking
is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future
events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking
statements or information contained in this news release are expressly qualified by this cautionary statement.